Lipocine (NASDAQ:LPCN – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Profitability
This table compares Lipocine and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipocine | -755.39% | -64.75% | -57.62% |
| Nutriband | -430.35% | -109.07% | -95.54% |
Volatility & Risk
Lipocine has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipocine | 1 | 1 | 0 | 0 | 1.50 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
Lipocine presently has a consensus price target of $15.00, indicating a potential upside of 594.44%. Given Lipocine’s higher probable upside, equities analysts plainly believe Lipocine is more favorable than Nutriband.
Valuation and Earnings
This table compares Lipocine and Nutriband”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lipocine | $1.98 million | 8.99 | -$9.63 million | ($1.79) | -1.21 |
| Nutriband | $2.04 million | 41.96 | -$8.23 million | ($0.53) | -13.28 |
Nutriband has higher revenue and earnings than Lipocine. Nutriband is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 4.7% of Lipocine shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Nutriband beats Lipocine on 8 of the 12 factors compared between the two stocks.
About Lipocine
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
